AC Immune SA uses its SupraAntigen and Morphomer technology platforms to develop therapeutics and diagnostics targeting misfolded proteins in neurodegenerative diseases. The company’s pipeline includes active immunotherapies and other candidates directed at tau and amyloid pathologies associated with Alzheimer’s disease and Parkinson’s disease, frequently advanced through partnerships with established pharmaceutical companies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1.3 | — | -21.2 | — |
| Q3 2025 | 0.9 | — | -15.9 | — |
| Q4 2025 | 0.3 | — | -14.4 | — |
| Q1 2026 | 1.1 | — | -14.8 | — |
| Q2 2026 | 15.1 | 1,057.2% | 1.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Amarin Corporation plc (AMRN), RideNow Group, Inc. (RDNW), enCore Energy Corp. (EU), Sutro Biopharma, Inc. (STRO), Magnitude International Ltd (MAGH), CAMP4 THERAPEUTICS CORPORATION (CAMP)